Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain can… Read more
Market Cap & Net Worth: Northwest Biotherapeutics Inc (NWBO)
Northwest Biotherapeutics Inc (OTCQB:NWBO) has a market capitalization of $323.54 Million ($323.54 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #12572 globally and #5375 in its home market, demonstrating a -8.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Northwest Biotherapeutics Inc's stock price $0.21 by its total outstanding shares 1540682082 (1.54 Billion).
Northwest Biotherapeutics Inc Market Cap History: 2015 to 2025
Northwest Biotherapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $4.93 Billion to $323.54 Million (-28.18% CAGR).
Northwest Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Northwest Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
312.15x
Northwest Biotherapeutics Inc's market cap is 312.15 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.93 Billion | $1.74 Million | -$114.74 Million | 2835.07x | N/A |
| 2016 | $536.31 Million | $623.00K | -$80.21 Million | 860.85x | N/A |
| 2017 | $362.37 Million | $336.00K | -$73.14 Million | 1078.48x | N/A |
| 2018 | $316.61 Million | $412.00K | -$35.79 Million | 768.47x | N/A |
| 2019 | $331.09 Million | $2.41 Million | -$20.30 Million | 137.38x | N/A |
| 2020 | $2.35 Billion | $1.29 Million | -$529.82 Million | 1819.94x | N/A |
| 2021 | $1.08 Billion | $1.00 Million | $179.13 Million | 1073.11x | 6.02x |
| 2022 | $1.20 Billion | $1.68 Million | -$105.03 Million | 714.04x | N/A |
| 2023 | $1.08 Billion | $1.93 Million | -$62.60 Million | 558.22x | N/A |
| 2024 | $431.39 Million | $1.38 Million | -$83.78 Million | 312.15x | N/A |
Competitor Companies of NWBO by Market Capitalization
Companies near Northwest Biotherapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Northwest Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Northwest Biotherapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Northwest Biotherapeutics Inc's market cap moved from $4.93 Billion to $ 323.54 Million, with a yearly change of -28.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $323.54 Million | -25.00% |
| 2024 | $431.39 Million | -60.00% |
| 2023 | $1.08 Billion | -10.26% |
| 2022 | $1.20 Billion | +11.43% |
| 2021 | $1.08 Billion | -54.10% |
| 2020 | $2.35 Billion | +609.63% |
| 2019 | $331.09 Million | +4.57% |
| 2018 | $316.61 Million | -12.63% |
| 2017 | $362.37 Million | -32.43% |
| 2016 | $536.31 Million | -89.12% |
| 2015 | $4.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Northwest Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $323.54 Million USD |
| MoneyControl | $323.54 Million USD |
| MarketWatch | $323.54 Million USD |
| marketcap.company | $323.54 Million USD |
| Reuters | $323.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.